Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 · New England Journal of Medicine · 11K citations
https://doi.org/10.1056/nejm200103153441101
D
Dennis J. Slamon
APLA Health(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
984
Papers
100.1K
Citations
126
h-index
345
i10-index
Dennis J. Slamon is an academic researcher from APLA Health. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Monoclonal and Polyclonal Antibodies Research & Advanced Breast Cancer Therapies. The author has an h-index of 126, co-authored 837 publications.
ORCID: 0000-0002-6330-498XPapers by this author
worksStudies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer
1989 · Science · 6,811 citations
https://doi.org/10.1126/science.2470152
Palbociclib and Letrozole in Advanced Breast Cancer
2016 · New England Journal of Medicine · 2,879 citations
https://doi.org/10.1056/nejmoa1607303
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
1999 · Journal of Clinical Oncology · 2,788 citations
https://doi.org/10.1200/jco.1999.17.9.2639
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
2011 · New England Journal of Medicine · 2,736 citations
https://doi.org/10.1056/nejmoa0910383
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
2015 · Cell · 1,943 citations
https://doi.org/10.1016/j.cell.2015.07.011
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat